DexCom, Inc. vs EPAM Systems Inc — how do they compare? DexCom, Inc. trades at $90.97 (market cap $33.79B), while EPAM Systems Inc trades at $100.36 (market cap $5.15B). The key difference: DexCom, Inc. is far larger — about 6.6× EPAM Systems Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, EPAM Systems Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | EPAM | |
|---|---|---|
Market Cap | $33.79B | $5.15B |
Sector | Health | Technology |
52-Week High | $89.53 | $221.40 |
52-Week Low | $54.84 | $76.04 |
Enterprise Value | $33.24B | $4.52B |
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
EPAM Systems trades at $99.00, up 1.67% today, with a bearish technical signal despite recent earnings beats. The stock shows attractive valuation metrics with a P/E of 13.55 and P/S of 0.97, while profitability remains solid with a net margin of 7.15%. Recent news highlights strong Q2 2026 earnings but a lowered revenue outlook due to slower North American growth and a new OpenAI partnership.
Outlook is mixed: strong fundamentals and analyst consensus ($117.27 target) support upside, but technical weakness and growth headwinds pose risks. Investment opportunity lies in valuation discount and AI initiatives, countered by demand volatility and competitive pressures.
Trailing returns across standard periods
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →